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Erratum to: MGMT methylation analysis of glioblastoma on 
the Infinium methylation BeadChip identifies two distinct CpG 
regions associated with gene silencing and outcome, yielding  
a prediction model for comparisons across datasets, tumor 
grades, and CIMP‑status
Pierre Bady · Davide Sciuscio · Annie‑Claire Diserens · Jocelyne Bloch · Martin J. van den Bent ·  
Christine Marosi · Pierre‑Yves Dietrich · Michael Weller · Luigi Mariani · Frank L. Heppner · 
David R. Macdonald · Denis Lacombe · Roger Stupp · Mauro Delorenzi · Monika E. Hegi 
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One of the methylation probe names in the abstract was 
misspelled and should read cg12434587 (not cg1243587).
The authors wish to add the following statement that was 
missing in the Acknowledgments:
The results published here are in part based upon data gener-
ated by The Cancer TCGA Genome Atlas pilot project estab-
lished by the NCI and NHGRI. Information about TCGA and 
the investigators and institutions who constitute the TCGA 
research network can be found at http://cancergenome.nih.
gov/. The dbGaP accession number to the specific version of 
the TCGA data set is phs000178.v5.p5.
Erratum to:  Acta Neuropathol (2012) 124:547–560  
DOI 10.1007/s00401‑012‑1016‑2
In the original paper, one of the author names was mis-
spelled and should read David R. Macdonald.
On behalf of the investigators of the European Organisation 
for Research and Treatment of Cancer and the National Cancer 
Institute of Canada Clinical Trials Group.
The online version of the original article can be found under 
doi:10.1007/s00401-012-1016-2.
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